证券之星消息，截至2026年2月4日收盘，春立医疗(688236)报收于23.03元，下跌1.24%，换手率 0.74%，成交量2.14万手，成交额4912.14万元。 2月4日的资金流向数据方面，主力资金净流入283.14万元，占总成交额5.76%，游资资金净流入216.54 万元，占总成交额4.41%，散户资金净流出499.68万元，占总成交额10.17%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-04 | 23.03 | -1.24% | 283.14万 | 5.76% | 216.54万 | 4.41% | -499.68万 | -10.17% | | 2026-02-03 | 23.32 | 0.95% | 63.18万 | 1.35% | -104.25万 | -2.23% | 41.07万 | 0.88% | | 2026-02-02 | 23.10 | - ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 | RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 | RMB | | 95,140,500 | | 2. ...

Core Viewpoint - Spring Medical experienced a decline of 1.24% on February 4, with a trading volume of 49.12 million yuan and a total market capitalization of 8.834 billion yuan [1] Company Overview - Spring Medical is a leading domestic orthopedic medical device manufacturer, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is currently in the design and inspection phase for a customized porous tantalum dental implant product [2] - Spring Medical has obtained registration certificates for hip and knee surgical robots and medical image processing software, indicating its investment in smart medical technology [2][3] Industry Position - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in the national evaluation of small and medium-sized enterprises, highlighting its strong innovation capabilities and market share [3] - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [5][8] Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan in the last three years [8] Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Central European Economic Selection Mixed A, both of which are new shareholders [9]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 | RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 | RMB | | 95,140,500 | | 2. ...

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Spring Medical (01858.HK), indicating a net reduction in holdings over the past trading days [1] - On February 2, 2026, southbound funds increased their holdings by 74,000 shares, marking a 0.18% increase [2] - Over the last five trading days, there were four days of net reductions, totaling a decrease of 405,800 shares [1][2] - In the last 20 trading days, there were 11 days of net reductions, with a cumulative decrease of 3,113,500 shares [1] Group 2 - As of February 2, 2026, southbound funds hold a total of 42,151,300 shares of Spring Medical, which represents 44.29% of the company's issued ordinary shares [1] - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [2] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and are sold in both domestic and international markets [2]

证券之星消息，截至2026年2月2日收盘，春立医疗(688236)报收于23.1元，下跌1.7%，换手率1.11%， 成交量3.21万手，成交额7586.53万元。 2月2日的资金流向数据方面，主力资金净流入93.69万元，占总成交额1.23%，游资资金净流入168.14万 元，占总成交额2.22%，散户资金净流出261.83万元，占总成交额3.45%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451.86万元，同比上升439.4%；负债率15.65%，投资收益321.7万元，财务费用-972.34万元，毛 利率67.27%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与销售。 该股最近90天内共有6家机构给出评级，买入评级6家； ...

Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of Spring Medical, indicating a recent stock price increase and overall market activity [1][2]. - As of February 2, Spring Medical's stock price rose by 2.00% to 23.97 CNY per share, with a total market capitalization of 9.194 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 5.73%, but has seen declines of 9.92% over the last five trading days and 11.42% over the last 60 days [1]. Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products being joint prosthetics and spinal implants [1]. - The company reported a revenue of 756 million CNY for the period from January to September 2025, reflecting a year-on-year growth of 48.75%, and a net profit of 192 million CNY, which is a 213.21% increase compared to the previous year [2]. - The company has distributed a total of 440 million CNY in dividends since its A-share listing, with 390 million CNY distributed over the last three years [3]. Group 3 - As of September 30, 2025, the number of shareholders for Spring Medical increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2]. - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and consumables, with relevant sectors including dental medical, medical devices, and orthopedic materials [2]. - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Fund, both of which are new entrants among the top ten circulating shareholders [3].

交易信息汇总资金流向 经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润为24,498.80万元至28,798.80万 元，同比上升96.01%至130.41%；扣除非经常性损益的净利润为22,953.60万元至26,953.60万元，同比上 升142.80%至185.11%。本期业绩增长主要因产品线纳入集采后释放增长潜力，推进国际化业务布局， 提升经营管理水平和经营效率。本次业绩预告未经注册会计师审计。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月30日主力资金净流出278.01万元，游资资金净流入516.47万元。 来自公司公告汇总：预计2025年净利润同比增长96.01%至130.41%，主要受益于集采释放增长潜 力及国际化业务推进。 1月30日主力资金净流出278.01万元，占总成交额2.59%；游资资金净流入516.47万元，占总成交额 4.81%；散户资金净流出238.46万元，占总成交额2.22%。 公司公告汇总2025年年度业绩预增公告 截至2026年1月30日收盘，春立医 ...

截至2026年1月30日收盘，春立医疗（688236）报收于23.5元，较上周的26.91元下跌12.67%。本周，春 立医疗1月26日盘中最高价报27.12元。1月30日盘中最低价报23.36元。春立医疗当前最新总市值90.14亿 元，在医疗器械板块市值排名45/127，在两市A股市值排名2233/5184。 本周关注点 业绩披露要点 春立医疗发布业绩预告，预计2025年全年归属净利润盈利2.45亿元至2.88亿元。 春立医疗发布业绩预告，预计2025年全年扣非后净利润盈利2.3亿元至2.7亿元。 经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润为24,498.80万元至28,798.80万 元，同比上升96.01%至130.41%；扣除非经常性损益的净利润为22,953.60万元至26,953.60万元，同比上 升142.80%至185.11%。本期业绩增长主要因产品线纳入集采后释放增长潜力，推进国际化业务布局， 提升经营管理水平和经营效率。本次业绩预告未经注册会计师审计。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 ...

中国经济网北京1月30日讯 春立医疗(688236.SH)今日收报23.50元，跌幅6.93%。目前该股处于破 发状态。 春立医疗于2021年12月30日在上交所科创板上市，发行价格为29.81元，发行股份数量3,842.80万 股，保荐机构为华泰联合证券有限责任公司，保荐代表人为张畅、茹涛。 春立医疗上市发行募集资金总额为114,553.87万元，扣除发行费用后募集资金净额为106,712.83万 元，较原拟募集资金净额少93287.17万元。 2021年12月27日，春立医疗发布的招股书显示，公司拟募集资金200,000.00万元，用于骨科植入 物及配套材料综合建设项目、研发中心建设项目、营销网络建设项目、补充流动资金项目。 春立医疗上市发行费用合计7,841.04万元，华泰联合证券有限责任公司获得保荐费用150.00万元、 承销费用6,523.59万元。 (责任编辑：徐自立) ...